MISTIE III.

Slides:

Advertisements

Similar presentations

1 Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage Mayer et al NEJM May 15, 2008 Elianna Saidenberg TM Resident.

Advertisements

Software Measurement and Process Improvement

Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical.

1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.

Steps in Using the and R Chart

1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.

Adaptive designs as enabler for personalized medicine

Marsha Lovett, Oded Meyer and Candace Thille Presented by John Rinderle More Students, New Instructors: Measuring the Effectiveness of the OLI Statistics.

ASSESSING LEARNING ALGORITHMS Yılmaz KILIÇASLAN. Assessing the performance of the learning algorithm A learning algorithm is good if it produces hypotheses.

Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.

1 OTC-TFM Monograph: Statistical Issues of Study Design and Analyses Thamban Valappil, Ph.D. Mathematical Statistician OPSS/OB/DBIII Nonprescription Drugs.

1 THE ROLE OF COVARIATES IN CLINICAL TRIALS ANALYSES Ralph B. D’Agostino, Sr., PhD Boston University FDA ODAC March 13, 2006.

WEEK25 PHYSICAL SCIENCE VOCABULARY. 1) DATA Information collected through observation and scientific research.

NDA SE-011 Docetaxel FDA Review. FDA Review Team Biostatistics –Clara Chu, PhD. –Gang Chen, PhD. Biopharmaceutics –Safaa Ibrahim PhD –Atiq Rahman,

Edward C. Jauch, MD, MS FACEP 1 Research Horizons in the Acute Management of ICH.

1 CBMTG 0601 Update 13-Feb-2009 Tampa, Florida. 22 Key Information Pivotal Phase III trial comparing G-PB with G-BM (experimental arm) 230 recipient-donor.

1 Mohamed Alosh, Ph.D. Kathleen Fritsch, Ph.D. Shiowjen Lee, Ph.D. DBIII, OB, CDER, FDA Efficacy Evaluation in Acne Clinical Trials.

Minimally Invasive Surgery plus rt-PA for Intracerebral Hemorrhage Evacuation The concept of minimally invasive evacuation of an ICH has a good rationale.

Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.

Division of Oncology Drug Products 1 AREAS OF MAJOR STATISTICAL CONCERNS IN THE M01 STUDY Overall (ITT Population) Finding Liver Metastasis Subgroup Finding.

M M M M 5. Not Listed

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.

Radiology Training Course. Timing of Imaging Studies.

CLEAR-III CT Radiology Course

NDE State of the Schools Adequate Yearly Progress Persistently Lowest Achieving Schools Nebraska Performance Accountability System Board of Education.

From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.

A cura di Filippo de Marinis

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2015 by the American Osteopathic Association.

Harrison CN et al. Proc ASH 2015;Abstract 59.

Swain SM et al. Proc SABCS 2012;Abstract P

Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun

DSMB Monitoring of the Therapeutic Hypothermia After Pediatric

Collecting & Displaying Data

Aiying Chen, Scott Patterson, Fabrice Bailleux and Ehab Bassily

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Section 7: Aggressive vs moderate approach to lipid lowering

The efficacy of 12 weeks non-surgical treatment for patients not eligible for total knee replacement: a randomized controlled trial with 1-year follow-up

Volume 141, Issue 2, Pages (August 2011)

Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun

Figure 5 Examples of biomarker-guided trials

Calendar Year 2009 Insure Oklahoma Total & Projected Enrollment

Scatter Plots and Equations of Lines

Longitudinal Trends in the Performance of Scientific Peer Reviewers

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis P.C. Minneci, K.J. Deans, P.Q. Eichacker, C. Natanson

Fig. 1. MAHALO clinical trial flowchart.

Review Questions III Compare and contrast the components of an individual score for a between-subject design (Completely Randomized Design) and a Randomized-Block.

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

The combined efficacy of multimodal non-surgical treatment on pain and sensitization in patients with knee osteoarthritis not eligible for a total knee.

Steps in Using the and R Chart

ACC 2003 Late Breaking Trials

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Volume 3, Issue 1, Pages (March 2017)

Volume 373, Issue 9658, Pages (January 2009)

Handling Missing Not at Random Data for Safety Endpoint in the Multiple Dose Titration Clinical Pharmacology Trial Li Fan*, Tian Zhao, Patrick Larson Merck.

Subhead Calibri 14pt, White

Helen Barraclough, MSc, Ramaswamy Govindan, MD

FIGURE 1. Flowchart of PnCRM7 clinical trial participants, primary efficacy cohort, and sub-populations used for efficacy analyses. Clinical trial participants.

Role of - Azilsartan - Azilsartan/chlorthalidone

A response-adaptive platform trial may start by enrolling a broad patient population and randomise patients equally across a range of treatments, shown.

Presentation transcript:

MISTIE III

Enrollment (n=500 eligible subjects)

Close-Out Timeline Final d180 collection: projected Feb 2018 DSMB review of d180 data: Jul 2018 Final d365 collection: projected Aug 2018 Primary and Secondary analyses complete: Fall 2018 Publication and ISC late-breaking presentation: Feb 2019

Figure 2. Efficacy of hematoma evacuation over time Figure 2. Efficacy of hematoma evacuation over time. A graph illustrating the distribution of clot evacuation rates in subjects randomized to the surgical arm in the first half of the trial. The plot also shows the overall consistency of ICH evacuation efficacy over time as demonstrated by average clot evacuation rate and percentage of subjects reaching target end-of-treatment volume < 15 mL. Two cases experienced hematoma size expansion by the end of treatment resulting in a negative clot evacuation rate.